Site Search

The United States spends $88 billion annually on cancer care, with patients paying nearly $4 billion in out-of-pocket costs. The 2019 ACS CAN health care forum examined best practices employers and other payers are using to contain costs while keeping coverage affordable for cancer ... to foster discussion and examine policies that are critical in the fight against cancer. We held our eighth annual National Forum on the Future of Health Care in April 2019 in Washington, D.C., where leaders from government, private and nonprofit organizations gathered to discuss ways to ...

LANSING, MI – As lawmakers dive into the new year, the American Cancer Society Cancer Action Network (ACS CAN) looks ahead to what public health initiatives our lawmakers can accomplish in the 2021 legislative session. Michigan has a long way to go ... legislation. This legislation would give chronically ill patients easier access to the cancer treatment they need. It would ensure the out-of-pocket cost to the patient for oral chemotherapy and intravenous chemotherapy are similar. Currently, the out-of-pocket costs for some oral chemotherapy ...

Overview The American Cancer Society Cancer Action Network (ACS CAN) empowers advocates across the country to make their voices heard and influence evidence-based public policy change, as well as legislative and regulatory solutions that will reduce the cancer burden. As part of this effort, ACS CAN deploys surveys to better understand cancer patient and survivor experiences and perspectives, through our Survivor Views ... less likely to stay up to date with preventive care if the provision mandating 100% coverage was repealed, resulting in a patient out-of-pocket cost for these services. Fifty-three percent put the dollar amount that would present a barrier to accessing preventive services at less than $200. ...

Clinical trials are an essential part of advancing new cancer treatments and reducing suffering and death from the disease. However, a significant percentage of cancer clinical trials never get off the ground because not enough patients enroll. We at ACS CAN are eager to better understand the barriers to clinical trial enrollment. So our policy experts spent the last year delving deep into patient ... decline to participate, most said they were afraid of side effects, losing control of their treatment or that they would encounter logistical or cost issues with enrolling. Clearly the cancer community needs to do more to expand the reach of available trials and make sure trials are designed ...